Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Outcomes After UCBT in MDS Patients Evaluated

Biol Blood Marrow Transplant; 2017 Jun; Gerds, et al

Publish date:

For some with hematologic malignancies, umbilical cord blood transplantation (UCBT) can lead to long-term disease-free survival, according to a study involving 176 individuals. But success is tempered by a high transplantation-related mortality (TRM) rate.

Participants with myelodysplastic syndrome underwent UCBT between 2004 and 2013. They were a median 56 years of age, with IPSS-R risk levels ranging from very low to very high. Among the results:

  • The 100-day probability of grade II-IV acute graft-versus-host disease (GVHD) was 38%.
  • The 3-year probability of chronic GVHD was 28%.
  • The probabilities of relapse and TRM at 3 years were 32% and 40%, respectively.
  • Increasing IPSS-R score at the time of transplant and pretransplant comorbidities were each linked with worse TRM, and lower disease-free and overall survival.
  • Those receiving reduced-intensity conditioning were nearly 4 times more likely to relapse.
  • The effect of conditioning regimen intensity was the same regardless of IPSS-R score.

Citation:

Gerds A, Woo A, Hu Z, et al. Outcomes after umbilical cord blood transplantation for myelodysplastic syndromes. Biol Blood Marrow Transplant. 2017;23(6):971-979. doi:10.1016/j.bbmt.2017.03.014.

This Week's Must Reads